Literature DB >> 10850706

Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand.

J C Boyington1, S A Motyka, P Schuck, A G Brooks, P D Sun.   

Abstract

Target cell lysis is regulated by natural killer (NK) cell receptors that recognize class I MHC molecules. Here we report the crystal structure of the human immunoglobulin-like NK cell receptor KIR2DL2 in complex with its class I ligand HLA-Cw3 and peptide. KIR binds in a nearly orthogonal orientation across the alpha1 and alpha2 helices of Cw3 and directly contacts positions 7 and 8 of the peptide. No significant conformational changes in KIR occur on complex formation. The receptor footprint on HLA overlaps with but is distinct from that of the T-cell receptor. Charge complementarity dominates the KIR/HLA interface and mutations that disrupt interface salt bridges substantially diminish binding. Most contacts in the complex are between KIR and conserved HLA-C residues, but a hydrogen bond between Lys 44 of KIR2DL2 and Asn 80 of Cw3 confers the allotype specificity. KIR contact requires position 8 of the peptide to be a residue smaller than valine. A second KIR/HLA interface produced an ordered receptor-ligand aggregation in the crystal which may resemble receptor clustering during immune synapse formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10850706     DOI: 10.1038/35014520

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  152 in total

1.  Signaling at the inhibitory natural killer cell immune synapse regulates lipid raft polarization but not class I MHC clustering.

Authors:  M S Fassett; D M Davis; M M Valter; G B Cohen; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

Review 2.  Structure and function of natural-killer-cell receptors.

Authors:  Peter D Sun
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  Host genes important to HIV replication and evolution.

Authors:  Amalio Telenti; Welkin E Johnson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 4.  Innate immune control of HIV.

Authors:  Mary Carrington; Galit Alter
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

5.  Antagonizing inhibition gets NK cells going.

Authors:  Sumati Rajagopalan; Eric O Long
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

6.  Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.

Authors:  Hugo G Hilton; Luca Vago; Anastazia M Older Aguilar; Achim K Moesta; Thorsten Graef; Laurent Abi-Rached; Paul J Norman; Lisbeth A Guethlein; Katharina Fleischhauer; Peter Parham
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

7.  Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity.

Authors:  Pravin Kumar; Ardeschir Vahedi-Faridi; Wolfram Saenger; Andreas Ziegler; Barbara Uchanska-Ziegler
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

8.  Host-specific adaptation of HIV-1 subtype B in the Japanese population.

Authors:  Takayuki Chikata; Jonathan M Carlson; Yoshiko Tamura; Mohamed Ali Borghan; Takuya Naruto; Masao Hashimoto; Hayato Murakoshi; Anh Q Le; Simon Mallal; Mina John; Hiroyuki Gatanaga; Shinichi Oka; Zabrina L Brumme; Masafumi Takiguchi
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11.

Authors:  Jingxian Liu; Ziwei Xiao; Hui Ling Ko; Meixin Shen; Ee Chee Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

10.  HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions.

Authors:  Y Yang; S Chen; F Yang; L Zhang; G Alterovitz; H Zhu; J Xuan; X Yang; H Luo; J Mu; L He; X Luo; Q Xing
Journal:  Pharmacogenomics J       Date:  2016-08-16       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.